Sugi Predict

Sugi Predict / Compounds / SCHEMBL4063049

SCHEMBL4063049

SCHEMBL4063049

CCO[Si](C)(C)CCCN1CCNCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCR4 P61073 2/20 0.42
▸ SIGMAR1 Q99720 1/20 0.37
▸ POLB P06746 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ GNAO1 P09471 4/20 0.35
▸ GNAI3 P08754 3/20 0.35
▸ GNAI1 P63096 3/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ DRD2 P14416 1/20 0.35
▸ DRD3 P35462 1/20 0.35
▸ SOD3 P08294 2/20 0.34
▸ HRH2 P25021 2/20 0.34
▸ HRH1 P35367 2/20 0.34
▸ HRH3 Q9Y5N1 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4065759 0.95 CXCR4 (0.43) CXCR4SIGMAR1POLBSMN1; SMN2HSD17B10
SCHEMBL4069045 0.89 POLB (0.37) CXCR4SIGMAR1POLBSMN1; SMN2HSD17B10
SCHEMBL774670 0.86 CXCR4 (0.42) CXCR4SIGMAR1POLBSMN1; SMN2HSD17B10
SCHEMBL2401145 0.84 CXCR4 (0.43) CXCR4SIGMAR1POLBSMN1; SMN2HSD17B10
SCHEMBL15492196 0.84 CXCR4 (0.46) CXCR4SIGMAR1POLBSMN1; SMN2HSD17B10
SCHEMBL21373220 0.84 PAOX (0.38) SIGMAR1GNAO1GNAI3GNAI1DRD3
SCHEMBL3358618 0.83 CXCR4 (0.42) CXCR4SIGMAR1POLBSMN1; SMN2HSD17B10
SCHEMBL7530676 0.83 CXCR4 (0.46) CXCR4SIGMAR1POLBSMN1; SMN2HSD17B10
SCHEMBL4065753 0.82 CXCR4 (0.44) CXCR4SIGMAR1POLBSMN1; SMN2HSD17B10
SCHEMBL16714779 0.82 HRH3 (0.45) SMN1; SMN2HRH3KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569691-B2 Protected piperazino group-bearing organoxysilane compound and making method SHIN-ETSU CHEMICAL CO., LTD. (JP) 2009-08-04 — — US claimed
CN-114573630-A Method for producing nitrogen-containing organooxysilane compound 信越化学工业株式会社 2022-06-03 — — CN disclosed
US-7569691-B2 Protected piperazino group-bearing organoxysilane compound and making method SHIN-ETSU CHEMICAL CO., LTD. (JP) 2009-08-04 — — US disclosed
EP-1714968-B1 Protected piperazino group-bearing organoxysilane compound and making method SHINETSU CHEMICAL CO (JP) 2008-07-16 — — EP disclosed
US-20060241294-A1 Protected piperazino group-bearing organoxysilane compound and making method SHIN-ETSU CHEMICAL CO., LTD. 2006-10-26 — — US disclosed
EP-1714968-A1 Protected piperazino group-bearing organoxysilane compound and making method Shin-Etsu Chemical Co., Ltd. (JP) 2006-10-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241294-A1 Protected piperazino group-bearing organoxysilane compound and making method PIEZO1, VCL, VIM CXCR4 3143/4885SIGMAR1 1050/4885POLB 1859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.